30 Apr, 2012, 08:00 ET
ALBANY, N.Y., April 30, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today SMARTSOURCING™, an approach that further focuses its research and contract manufacturing services on the various needs of the life sciences and other industries. AMRI SMARTSOURCING™ is a series of strategic sourcing options for customers to reach more successful outcomes. SMARTSOURCING™ is based on 21 years of industry-leading experience and global locations, and combines high quality scientific performance and enhanced decision-making with the accountability of delivering results in a cost-competitive manner.
Pharmaceutical companies are under pressure to deliver accelerated and increased drug discovery success with reduced budgets and resources. This can result in a loss of productivity where compromises, such as putting price before quality, scientific expertise and even manufacturing capability, are often struck. Furthermore, following substantial downsizing in the United States and Europe, many large pharmaceutical companies are losing experienced scientists with drug discovery and development expertise and relying more on their providers to fill critical knowledge gaps. As a result, CROs and CMOs need to reconsider their current service strategies to find more appropriate ways to meet the market's changing needs.
AMRI has taken this challenge and recently made significant changes to build a stronger, more agile organization for our customers. SMARTSOURCING™ is a pioneering approach for the industry that is fit for purpose in today's world and puts the power of decision making, without compromise, in the hands of the customer.
SMARTSOURCING™ is a means of insourcing or outsourcing, or even a hybrid model of both, which can deliver high quality performance and scientific expertise, built on a foundation of 21 years of accomplishment delivering customer IND candidates and API manufacturing successes. It means tapping into AMRI's people, knowhow, facilities, expertise and global project management to provide exactly what is needed across the discovery, development and manufacturing process.
"Pharma companies are looking for more supplier accountability, greater trust and consultation," said Thomas E. D'Ambra, Ph.D., President and CEO of AMRI. "They want a better balance of risk, but also greater flexibility and tailored business models that address their unique needs."
Dr. D'Ambra continued, "With SMARTSOURCING™, we offer customers innovative and strategic collaborative partnerships, without compromising quality or lowering expectations. We look forward to working with our customers as we continue to provide creative and flexible outsourcing solutions."
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.
Share this article